• Citer

A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)

par Rao, Sheela;Anandappa, Gayathri;Capdevila, Jaume;Dahan, Laëtitia;Evesque, Ludovic;Kim, Stefano;Saunders, Mark M.P.;Gilbert, Duncan D.C.;Jensen, Lars Henrik;Samalin, Emmanuelle;Spindler, Karen Lise Garm K.L.;Tamberi, Stefano;Demols, Anne ;Guren, Marianne M.G.;Arnold, Dirk;Fakih, Marwan;Kayyal, T.;Cornfeld, M.;Tian, C.;Catlett, M.;Smith, M.;Spano, Jean Philippe
Référence ESMO Open, 7, 4, 100529
Publication Publié, 2022-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)
Auteur:	Rao, Sheela; Anandappa, Gayathri; Capdevila, Jaume; Dahan, Laëtitia; Evesque, Ludovic; Kim, Stefano; Saunders, Mark M.P.; Gilbert, Duncan D.C.; Jensen, Lars Henrik; Samalin, Emmanuelle; Spindler, Karen Lise Garm K.L.; Tamberi, Stefano; Demols, Anne; Guren, Marianne M.G.; Arnold, Dirk; Fakih, Marwan; Kayyal, T.; Cornfeld, M.; Tian, C.; Catlett, M.; Smith, M.; Spano, Jean Philippe
Informations sur la publication:	ESMO Open, 7, 4, 100529
Statut de publication:	Publié, 2022-08
Sujet CREF:	Généralités
Mots-clés:	anal cancer
	clinical trial
	INCMGA00012
	PD-(L)1 inhibitor
	phase II
	retifanlimab
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:2059-7029
	info:doi/10.1016/j.esmoop.2022.100529
	info:pii/S2059702922001508
	info:scp/85133951152
	info:pmid/35816951